/Companies

Shuttle Pharmaceuticals Holdings

NASDAQ: SHPH

Gaithersburg, US · Founded 2018 · Delaware corporation

Find your way into Shuttle Pharmaceuticals Holdings

Sign up to see every warm intro you have to Shuttle Pharmaceuticals Holdings

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Shuttle Pharmaceuticals Holdings team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.

Founders & leadership

Shuttle Pharmaceuticals Holdings was founded in 2018 by Mira Jung and Anatoly Dritschilo.

MJ
Mira JungChief Scientific Officer for Biology
AD
Anatoly DritschiloChief Executive Officer and Chairman
MV
Michael Vander HoekVice President - Operations and Regulatory
TRTyvin Rich
Tyvin RichChief Medical Officer
TLTimothy Lorber
Timothy LorberChief Financial OfficerTimothy Lorber previously served as CFO and head of human resources and IT at a mid-Atlantic seafood processing and distribution company, and held finance roles at Legg Mason and Freddie Mac with experience in M&A, valuations, and financial reporting across investment management, financial services, and real estate sectors.
PDPeter Dritschilo
Peter DritschiloChief Operating Officer2012–2025Peter Dritschilo is President and Chief Operating Officer of Shuttle Pharmaceuticals Holdings, which operates Molecule.ai, an AI-driven platform for molecular discovery and early-stage drug development. He brings over 25 years of experience in oncology operations, having led hospital-based and freestanding cancer programs across radiation oncology, surgical oncology, and stem cell transplantation, and has supported biotech companies through capital raises and IPO processes.

Board

AH
Amir HeshmatpourBoard director
JS
Joshua SchaferBoard director
CS
Chris SenanayakeBoard director
SR
Steven RichardsBoard director
BJ
Bette JacobsBoard director
MB
Milton BrownBoard director

Reported raises · per SEC filings

Form D private placements

$23.4M disclosed across 9 of 10 rounds · 1900–2026

▶$10MraisedMay 2026 · 47 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan TrasoliniExecutive Officer
  • Adam ChambersDirector
  • Yuying LiangExecutive Officer
  • George ScorsisDirector
  • Angel LirianoDirector
  • Christopher CooperExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
Sales commissions
$1M
Placement agents
E.F. Hutton & Co.
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedNov 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher CooperExecutive Officer, Director
  • Tyvin RichExecutive Officer
  • Adam ChambersDirector
  • Mira JungExecutive Officer
  • Angel LirianoDirector
  • Sachin PathigodaDirector
  • George ScorsisDirector
  • Timothy LorberExecutive Officer
  • Oleh NabytDirector
Offering amount
$2.5M
Amount sold
$2.5M
Sales commissions
$100K
Placement agents
WestPark Capital, Inc.
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedJun 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mira JungExecutive Officer
  • Tyvin RichExecutive Officer
  • George ScorcisDirector
  • Timothy LorberExecutive Officer
  • Steven RichardsDirector
  • Joseph TungDirector
  • Peter DritschiloExecutive Officer
  • Christopher CooperExecutive Officer
  • Oleh NabytDirector
Offering amount
$4.3M
Amount sold
$4.3M
Sales commissions
$170K
Placement agents
WestPark Capital, Inc.
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$790KraisedOct 2024 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joshua SchaferDirector
  • Chris SenanayakeDirector
  • Michael Vander HoekExecutive Officer
  • Steven RichardsDirector
  • Tyvin RichExecutive Officer
  • Timothy LorberExecutive Officer
  • Mira JungExecutive Officer
  • Bette JacobsDirector
  • Anatoly DritschiloExecutive Officer, Director
  • Milton BrownDirector
  • Peter DritschiloExecutive Officer
Offering amount
$1.3M
Amount sold
$790K
Minimum investment
$95K
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJan 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Mira JungExecutive Officer
  • Milton BrownDirector
  • Steven RichardsDirector
  • Michael Vander HoekExecutive Officer
  • Anatoly DritschiloExecutive Officer, Director
  • Joshua SchaferDirector
  • Chris SenanayakeDirector
  • Bette JacobsDirector
  • Peter DritschiloExecutive Officer
  • Tyvin RichExecutive Officer
Offering amount
$4M
Amount sold
$4M
Minimum investment
$4M
Sales commissions
$320K
Placement agents
Boustead Securities, LLC
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$125KraisedAug 2022 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Anatoly DritschiloExecutive Officer, Director
  • Joshua SchaferDirector
  • Mira JungExecutive Officer
  • Steven RichardsDirector
  • Michael Vander HoekExecutive Officer
  • Chris SenanayakeDirector
  • William AdkinsDirector
  • Milton BrownExecutive Officer, Director
  • Peter DritschilloExecutive Officer
  • Tyvin RichExecutive Officer
Offering amount
$500K
Amount sold
$125K
Minimum investment
$25K
Sales commissions
$12.5K
Placement agents
Boustead Securities, LLC
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$365KraisedFeb 2022 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William AdkinsDirector
  • Mira JungExecutive Officer
  • Michael Vander HoekExecutive Officer
  • Steven RichardsDirector
  • Chris SenanayakeDirector
  • Joshua SchaferDirector
  • Anatoly DritschiloExecutive Officer, Director
  • Milton BrownExecutive Officer, Director
  • Tyvin RichExecutive Officer
  • Peter DritschilloExecutive Officer
Offering amount
$2M
Amount sold
$365K
Minimum investment
$25K
Sales commissions
$36.5K
Placement agents
Boustead Securities, LLC
First sale
Feb 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedJan 2022 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven RichardsDirector
  • William AdkinsDirector
  • Anatoly DritschiloExecutive Officer, Director
  • Mira JungExecutive Officer
  • Michael Vander HoekExecutive Officer
  • Milton BrownDirector
  • Peter DritschiloExecutive Officer, Director
  • Josh SchaferDirector
  • Chris SenanayakeDirector
  • Tyvin RichExecutive Officer
Offering amount
$500K
Amount sold
$500K
Minimum investment
$250K
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 9

TipRanksFinancial analysis and stock research platform.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
trefisTrefis operates thinkHub, a data-driven investment analytics platform that uses what it calls "Understandable-AI" — an auditable, non-black-box decision system — to build and run equity portfolios (such as its High-Quality, Bayesian, and Reinforced Value strategies) aimed at outperforming the S&P 500. It serves investors and money managers, offering peer comparisons, valuation, and macro-event analyses, with practical investing carried out via an affiliated firm.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
SoFiSoFi Technologies is a digital personal-finance company offering student and personal loans, mortgages, investing, banking and credit cards through one app; it went public on the Nasdaq in 2021 via SPAC.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies working in the same space as Shuttle Pharmaceuticals Holdings.

Frequently asked questions

What does Shuttle Pharmaceuticals Holdings do?
Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.
Who founded Shuttle Pharmaceuticals Holdings?
Shuttle Pharmaceuticals Holdings was founded by Mira Jung, Anatoly Dritschilo in 2018.
How much funding has Shuttle Pharmaceuticals Holdings raised?
Shuttle Pharmaceuticals Holdings has disclosed $23.4M raised across 9 of its 10 known rounds.
Where is Shuttle Pharmaceuticals Holdings headquartered?
Shuttle Pharmaceuticals Holdings is headquartered in Gaithersburg, US.